Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis

Neuroendocrine Tumors Clinical Trial

— HET-NET  

Official title:

Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02646644
• Other study ID #: 201501247
• Status: Completed
• Start date: January 2016
• Est. completion date: May 2017

Study information

• Verified date: May 2024
• Source: University Medical Center Groningen
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In an individual cancer patient extensive genetic and phenotypic variation exists between and within tumor lesions. Tumour load in NET patients can be measured with fluorine-18-L-dihydroxyphenylalaninepositron emission tomography (18F-DOPA-PET) scan.

This aim of the study is to investigate heterogeneity between tumor lesions within patients with intestinal NET by determining the differences in tracer uptake measured on a 18F- DOPA-PET scan retrospectively.

Description:

In an individual cancer patient extensive genetic and phenotypic variation exists between and within tumor lesions. Tumour load in NET patients can be measured with fluorine-18-L-dihydroxyphenylalanine positron emission tomography (18F-DOPA-PET) scan.

This aim of the study is to investigate heterogeneity between tumor lesions within patients with intestinal NET by determining the differences in tracer uptake measured on a 18F- DOPA-PET scan in retrospect.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: May 2017
• Est. primary completion date: May 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• age =18 years

• diagnosis of intestinal NET diagnosed by a dedicated NET specialist

• more than one positive lesion on the 18F-DOPA-PET scan.

• available CT-scan within 6 months before or after the 18F-DOPA-PET-scan.

Exclusion Criteria:

• no clinical data available at the UMCG, besides the results of the DOPA PET scan.

Related Conditions & MeSH terms

• Neuroendocrine Tumors

Intervention

Other:
• Metastasized intestinal NET
This is an observational study

Locations

Country	Name	City	State
Netherlands	University Medical Center Groningen	Groningen

Sponsors (1)

Lead Sponsor	Collaborator
University Medical Center Groningen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	the correlation of the magnitude of heterogeneity with ki 67	the correlation of the magnitude of heterogeneity between tumor lesions within patients with Intestinal NET, with the ki67 index of the tumor	date of diagnosis until date of scan
Primary	tracer uptake in tumor lesions within patients with intestinal NET	The difference in tracer uptake of tumor lesions within patients with intestinal NET measured on a 18F- DOPA-PET scan.	at the day of scan
Secondary	tracer uptake in tumor lesions within patients with intestinal NET adjusted for uptake of background organ	The difference in tracer uptake of tumor lesions adjusted for uptake of background organ within patients with intestinal NET measured on a 18F- DOPA-PET scan.	at the day of scan